Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 261-267

  Matsunaga, Yuko ^a   Inoue, Hiromasa ^a,b   Fukuyama, Satoru ^a   Yoshida, Hideyuki ^c   Moriwaki, Atsushi ^a   Matsumoto, Takafumi ^a   Matsumoto, Koichiro ^a   Asai, Yukari ^a   Kubo, Masato ^d   Yoshimura, Akihiko ^c   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

Allergic asthma; JAK inhibitor; JAK STAT; Nanoparticle; Th17; Th2; Treg

Indexed keywords

CELL MARKER; EOTAXIN; GOB 5 PROTEIN; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 17; JANUS KINASE INHIBITOR; OVALBUMIN; POLYGLACTIN; PYRIDONE 6; STAT6 PROTEIN; UNCLASSIFIED DRUG;

AIRWAY DYNAMICS; AIRWAY HYPERRESPONSIVENESS; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYMATIC DEGRADATION; EOSINOPHILIA; EPITHELIUM CELL; GOBLET CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LUNG LAVAGE; LYMPHOCYTE DIFFERENTIATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; T LYMPHOCYTE; TH17 CELL; TH2 CELL; TRACHEA MUCOSA;

ANIMALS; ASTHMA; BENZIMIDAZOLES; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; CAPSULES; CHLORIDE CHANNELS; EOSINOPHILIA; INTERLEUKIN-13; JANUS KINASES; LACTIC ACID; LUNG; MICE; MUCOPROTEINS; NANOPARTICLES; OVALBUMIN; POLYGLYCOLIC ACID; PROTEIN KINASE INHIBITORS; PYRIDONES; STAT6 TRANSCRIPTION FACTOR; TH2 CELLS;

MURINAE; MUS;

EID: 78650875942     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.104     Document Type: Article

References (25)

1. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol. Rev. 2004, 202:175-190.
2. Kudlacz E., Conklyn M., Andresen C., Whitney-Pickett C., Changelian P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur. J. Pharmacol. 2008, 582:154-161.
3. Schindler C.W. Series introduction. JAK-STAT signaling in human disease. J. Clin. Invest. 2002, 109:1133-1137.
4. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
5. Wan Y.Y., Flavell R.A. How diverse-CD4 effector T cells and their functions. J. Mol. Cell Biol. 2009, 1:20-36.
6. Schnyder-Candrian S., Togbe D., Couillin I., Mercier I., Brombacher F., Quesniaux V., Fossiez F., Ryffel B., Schnyder B. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 2006, 203:2715-2725.
7. Wakashin H., Hirose K., Maezawa Y., Kagami S., Suto A., Watanabe N., Saito Y., Hatano M., Tokuhisa T., Iwakura Y., Puccetti P., Iwamoto I., Nakajima H. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am. J. Respir. Crit. Care Med. 2008, 178:1023-1032.
8. + regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J. Allergy Clin. Immunol. 2008, 122:617-624. e616.
9. Thompson J.E., Cubbon R.M., Cummings R.T., Wicker L.S., Frankshun R., Cunningham B.R., Cameron P.M., Meinke P.T., Liverton N., Weng Y., DeMartino J.A. Photochemical preparation of a pyridone containing tetracycle: a JAK protein kinase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12:1219-1223.
10. Pedranzini L., Dechow T., Berishaj M., Comenzo R., Zhou P., Azare J., Bornmann W., Bromberg J. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006, 66:9714-9721.
11. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
12. Hara K., Tsujimoto H., Tsukada Y., Huang C.C., Kawashima Y., Tsutsumi M. Histological examination of PLGA nanospheres for intratracheal drug administration. Int. J. Pharm. 2008, 356:267-273.
13. Kibe A., Inoue H., Fukuyama S., Machida K., Matsumoto K., Koto H., Ikegami T., Aizawa H., Hara N. Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. Am. J. Respir. Crit. Care Med. 2003, 167:50-56.
14. Ichiyama K., Yoshida H., Wakabayashi Y., Chinen T., Saeki K., Nakaya M., Takaesu G., Hori S., Yoshimura A., Kobayashi T. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J. Biol. Chem. 2008, 283:17003-17008.
15. Nakano T., Inoue H., Fukuyama S., Matsumoto K., Matsumura M., Tsuda M., Matsumoto T., Aizawa H., Nakanishi Y. Niflumic acid suppresses interleukin-13-induced asthma phenotypes. Am. J. Respir. Crit. Care Med. 2006, 173:1216-1221.
16. Fukuyama S., Inoue H., Aizawa H., Oike M., Kitaura M., Yoshie O., Hara N. Effect of eotaxin and platelet-activating factor on airway inflammation and hyperresponsiveness in guinea pigs in vivo. Am. J. Respir. Crit. Care Med. 2000, 161:1844-1849.
17. Nakanishi A., Morita S., Iwashita H., Sagiya Y., Ashida Y., Shirafuji H., Fujisawa Y., Nishimura O., Fujino M. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc. Natl. Acad. Sci. USA 2001, 98:5175-5180.
18. Zhou Y., Dong Q., Louahed J., Dragwa C., Savio D., Huang M., Weiss C., Tomer Y., McLane M.P., Nicolaides N.C., Levitt R.C. Characterization of a calcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma. Am. J. Respir. Cell Mol. Biol. 2001, 25:486-491.
19. Ozdemir C., Akdis M., Akdis C.A. T regulatory cells and their counterparts: masters of immune regulation. Clin. Exp. Allergy 2009, 39:626-639.
20. Molet S., Hamid Q., Davoine F., Nutku E., Taha R., Page N., Olivenstein R., Elias J., Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 2001, 108:430-438.
21. He R., Oyoshi M.K., Jin H., Geha R.S. Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc. Natl. Acad. Sci. USA 2007, 104:15817-15822.
22. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
23. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., Blank R.B., Meylan F., Siegel R., Hennighausen L., Shevach E.M., O'Shea J J. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26:371-381.
24. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
25. Zeiser R., Negrin R.S. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008, 7:458-462.